51 Recruiting Studies Using Ribociclib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Ribociclib
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
📍 UCLA Jonsson Comp Cancer Center — Los Angeles, California
Breast Cancer
View Study & Checklist ➔TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
📍 Stanford Women's Cancer Center — Palo Alto, California
Breast Cancer
View Study & Checklist ➔Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
📍 Research Site — Tucson, Arizona
Locally Advanced (Inoperable) or Metastatic Breast Cancer
View Study & Checklist ➔First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
📍 California Cancer Associates for Research and Excellence — Encinitas, California
Advanced Cancer
View Study & Checklist ➔Study of INCB123667 in Subjects With Advanced Solid Tumors
📍 City of Hope Medical Center — Duarte, California
Solid Tumors
View Study & Checklist ➔Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
📍 Pfizer New York — New York, New York
Breast Cancer
View Study & Checklist ➔Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
📍 Dothan Hematology and Oncology — Dothan, Alabama
Breast Cancer
View Study & Checklist ➔A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
📍 University of Alabama at Birmingham-Kirklin Clinic — Birmingham, Alabama
Early Breast Cancer
View Study & Checklist ➔Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
📍 The Angeles Clinic and Research Institute — Los Angeles, California
Melanoma
View Study & Checklist ➔Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
📍 Barrow Brain and Spine — Phoenix, Arizona
Glioblastoma Multiforme
View Study & Checklist ➔Ribociclib and Bicalutamide in AR+ TNBC
📍 University of Illinois Cancer Center — Chicago, Illinois
Triple Negative Breast Cancer
View Study & Checklist ➔Roll-over Study to Allow Continued Access to Ribociclib
📍 Ironwood Cancer and Research Centers — Chandler, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
📍 University of Pennsylvania Hospital — Philadelphia, Pennsylvania
Breast Neoplasm
View Study & Checklist ➔Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
📍 Novartis Investigative Site — Toronto, Ontario
EGFR-mutant Non-small Cell Lung Cancer
View Study & Checklist ➔Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
📍 Children's Hospital Colorado — Aurora, Colorado
Acute Lymphoblastic Leukemia ALL
View Study & Checklist ➔Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
📍 Massachusetts General Hospital — Boston, Massachusetts
KRAS G12C Mutant Solid Tumors
View Study & Checklist ➔Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
📍 Research Site — Phoenix, Arizona
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Soft Tissue Sarcoma
View Study & Checklist ➔Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Breast Cancer
View Study & Checklist ➔A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
📍 Lyndon Baines Johnson General Hospital — Houston, Texas
Recurrent Endometrial Carcinoma
View Study & Checklist ➔Ribociclib and Letrozole Treatment in Ovarian Cancer
📍 University of California, San Francisco — San Francisco, California
Low Grade Serous Carcinoma
View Study & Checklist ➔Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
📍 The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
📍 Los Angeles Cancer Network — Los Angeles, California
Breast Cancer
View Study & Checklist ➔Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Breast Cancer
View Study & Checklist ➔Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
📍 Clinical Trial Site — Hot Springs, Arkansas
Breast Cancer
View Study & Checklist ➔Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
📍 Central Alabama Research — Birmingham, Alabama
Early Breast Cancer
View Study & Checklist ➔A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
📍 Los Angeles Cancer Network - Anaheim — Anaheim, California
Breast Cancer
View Study & Checklist ➔Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
📍 Huntsman Cancer Institute — Salt Lake City, Utah
Metastatic Breast Cancer
View Study & Checklist ➔Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
📍 NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
📍 The University of Arizona Cancer Center — Tucson, Arizona
PIK3CA Mutation
View Study & Checklist ➔The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
📍 Research Site — St Louis, Missouri
ER+ HER2- Advanced Breast Cancer
View Study & Checklist ➔Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
📍 Yale University — New Haven, Connecticut
HER2 Negative Breast Cancer
View Study & Checklist ➔First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
📍 Ellison Clinic at Saint John's — Los Angeles, California
Breast Cancer
View Study & Checklist ➔Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
📍 University of Michigan — Ann Arbor, Michigan
Breast Cancer
View Study & Checklist ➔A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
Breast Neoplasms
View Study & Checklist ➔BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
📍 Alabama Oncology Princeton — Birmingham, Alabama
HR+/HER2- Breast Cancer
View Study & Checklist ➔Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Locoregional Recurrence
View Study & Checklist ➔Study of AVZO-021 in Patients With Advanced Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
📍 City of Hope — Duarte, California
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
View Study & Checklist ➔A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
📍 Northwestern Memorial Hospital — Chicago, Illinois
HR+/HER2-negative Breast Cancer
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
📍 City of Hope — Duarte, California
Metastatic Breast Cancer
View Study & Checklist ➔Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
📍 University of California LA — Los Angeles, California
Advanced HR+/HER2- Breast Cancer
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
📍 Southern Cancer Center — Daphne, Alabama
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
View Study & Checklist ➔Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
📍 Children's Hospital Colorado — Aurora, Colorado
High Grade Glioma
View Study & Checklist ➔Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Solid Tumor, Adult
View Study & Checklist ➔A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
📍 Research Site — Duarte, California
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
📍 Research Site — Gilbert, Arizona
Advanced Breast Cancer
View Study & Checklist ➔